Deep Track Capital LP Sells 485,187 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Deep Track Capital LP trimmed its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 39.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 750,000 shares of the company's stock after selling 485,187 shares during the period. Deep Track Capital LP owned approximately 2.14% of Oruka Therapeutics worth $14,542,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ORKA. Vanguard Group Inc. increased its stake in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after acquiring an additional 1,572,853 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Oruka Therapeutics by 374.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock valued at $25,730,000 after purchasing an additional 1,047,245 shares during the last quarter. FMR LLC raised its holdings in shares of Oruka Therapeutics by 17.7% during the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after buying an additional 830,000 shares in the last quarter. Franklin Resources Inc. purchased a new position in Oruka Therapeutics in the 3rd quarter worth $17,661,000. Finally, Braidwell LP boosted its position in Oruka Therapeutics by 122.5% during the fourth quarter. Braidwell LP now owns 1,147,676 shares of the company's stock valued at $22,253,000 after buying an additional 631,950 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the company's stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the purchase, the insider now directly owns 4,148,428 shares of the company's stock, valued at approximately $47,458,016.32. This represents a 2.19 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have purchased a total of 98,339 shares of company stock valued at $1,128,456 in the last ninety days. Corporate insiders own 22.67% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ORKA shares. HC Wainwright reissued a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wedbush reiterated an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Friday, March 7th. Finally, Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of "Buy" and a consensus price target of $39.86.

Oruka Therapeutics Trading Down 2.2 %

NASDAQ:ORKA traded down $0.21 on Friday, reaching $9.54. 104,045 shares of the stock traded hands, compared to its average volume of 231,593. The company's fifty day simple moving average is $9.95 and its 200 day simple moving average is $15.56. The company has a market capitalization of $357.19 million, a price-to-earnings ratio of -1.52 and a beta of 0.25. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.19. Equities analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.